-+ 0.00%
-+ 0.00%
-+ 0.00%

Champions Oncology Q1 FY27 adjusted EBITDA more than doubled to $671,000; revenue rises 8.8% to $15.2 million

PUBT·09/10/2026 20:00:48
Listen to the news
Champions Oncology Q1 FY27 adjusted EBITDA more than doubled to $671,000; revenue rises 8.8% to $15.2 million
  • Champions Oncology posted revenue of USD 15.2 million, up 8.8% year over year, for fiscal Q1 ended July 31, 2026.
  • GAAP net loss narrowed to USD 426,000; GAAP operating loss tightened to USD 409,000.
  • Oncology services margin expanded 8 percentage points to 51%, helped by lower third-party radiolabeling costs.
  • Non-GAAP adjusted EBITDA more than doubled to USD 671,000 as improved study execution lifted conversion of contracted work into revenue.
  • Management cited increased commercial activity in data offerings while continuing investment in the commercial organization, data platform, radiopharmaceutical capabilities, and target discovery.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Champions Oncology Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202609101600ACCESSWRNAPR_____1219255) on September 10, 2026, and is solely responsible for the information contained therein.